A Drug-Coated Balloon Treatment for Urethral Stricture Disease: Three-Year Results from the ROBUST I Study
Ramón Virasoro,Jessica M DeLong,Rafael E Estrella,Merycarla Pichardo,Ramón Rodriguez Lay,Gustavo Espino,Sean P Elliott
DOI: https://doi.org/10.2147/RRU.S359872
2022-05-06
Research and Reports in Urology
Abstract:Ramón Virasoro, 1 Jessica M DeLong, 1 Rafael E Estrella, 2 Merycarla Pichardo, 3 Ramón Rodriguez Lay, 4 Gustavo Espino, 5 Sean P Elliott 6 1 Urology of Virginia PLLC, Virginia Beach, VA, USA; 2 Clinica Unión Medica, Santiago de los Caballeros, Dominican Republic; 3 URUS, Santo Domingo, Dominican Republic; 4 Cirujano Urologo Royal Center Panama City, Panama City, Panama; 5 Centro Especializado San Fernando, Panama City, Panama; 6 Department of Urology, University of Minnesota, Minneapolis, MN, USA Correspondence: Ramón Virasoro, Urology of Virginia PLLC, 225 Clearfield Ave, Virginia Beach, VA, 23462, USA, Tel +1 757-457-5100, Email Introduction: Endoscopic management of male anterior urethral stricture disease is common; however, repeat treatment is associated with high recurrence rates. Here, we report the 3-year results of the ROBUST I trial, which evaluated the safety and efficacy of the Optilume ® drug coated balloon (DCB) in men with recurrent urethral strictures. Methods: Adult men with recurrent bulbar urethral strictures ≤ 2 cm in length and 1– 4 prior endoscopic interventions were treated with the Optilume DCB. Functional success was defined as ≥ 50% reduction in International Prostate Symptom Score (IPSS) without need for retreatment. Other outcomes included quality of life, maximum flow rate, post-void residual urine volume, erectile function, and freedom from repeat intervention. Results: Of the 53 enrolled and treated men, 33 completed the 3-year visit, with 10 patients experiencing clinical failures at previous visits, giving a total of 43 subjects evaluable for the functional success endpoint. Functional success was achieved in 67% (29/43) and freedom from retreatment in 77% (33/43). Average IPSS improved from 25.2 at baseline to 5.5 at 3 years (p< 0.0001). Significant improvements were observed in quality of life, flow rate, and post-void residual urine volume. Erectile function was not affected by treatment. Device-related adverse events were mild or moderate in nature and resolved quickly after onset. There were no serious treatment-related adverse events. Conclusion: Symptomatic improvement after treatment with the Optilume DCB was maintained through 3 years in a population highly susceptible to recurrent urethral stricture disease. This minimally invasive therapy is safe with no negative impact on sexual function. Keywords: lower urinary tract symptoms, paclitaxel, urethral dilation, medical device, clinical trial The treatment of recurrent male anterior urethral stricture disease remains a common and challenging problem for many urologists across the globe. Current available options for recurrent urethral strictures include endoscopic management and urethral reconstruction. While open repair is considered the gold standard, with success rates of 80–95%, minimally invasive therapies are still more frequently used. 1 Of the primary endoscopic procedures, urethral dilation and Direct Vision Internal Urethrotomy (DVIU) have similar efficacy, with progressively lower probability of long-term success in repeat treatments. 2,3 More recently, small studies have evaluated targeted injections of antifibrotic agents as an adjunctive therapy to endoscopic procedures in an attempt to prevent or attenuate scar tissue formation. 4 The Optilume ® Drug Coated Balloon (DCB) (Urotronic, Inc., Plymouth, MN, USA) is the first DCB intended for the treatment of male anterior urethral strictures. This technology aims to provide immediate symptomatic relief by widening the urethral lumen using balloon dilation, while maintaining long-term urethral patency via the circumferential and local application of paclitaxel. Paclitaxel is an antimitotic agent that inhibits cell proliferation and migration and has been used extensively in cardiovascular interventions to prevent restenosis after angioplasty. 5,6 We previously reported the 1- and 2-year ROBUST I trial results, which evaluated the Optilume ® DCB in men with recurrent urethral strictures up to 2 cm in length. 7,8 Anatomic success in ROBUST I was achieved in 70% at 1 year based on the ability to pass a 16F flexible cystoscope or 14F Foley catheter. 7 Based on the study design, cystoscopy was not performed after 1 year, however functional success occurred in 70% (32/46) at 2 years, defined as International Prostate Symptom Score (IPSS) improvement ≥50% in the absence of retreatment need. 8 We now report the 3-year safety and efficacy outcomes of the ROBUST I trial. ROBUST I is a prospective, multicenter, single arm, open-label study evaluating the -Abstract Truncated-